ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,328Medicare Part D Prescriptions Filled, Including Refills

Rank: 43 out of 229

$535K Total Retail Price of All Prescriptions

Rank: 40 out of 229

861 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
29% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 861 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

5% of this provider’s 861 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

2% of this provider’s 7,861 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$57 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

11 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
LEVOTHYROXINE SODIUM 628 541 1 1
LISINOPRIL 460 393 2 2
AMLODIPINE BESYLATE 414 367 3 5
SIMVASTATIN 330 288 4 3
METFORMIN HCL 323 277 5 6
HYDROCHLOROTHIAZIDE 298 270 6 9
OMEPRAZOLE 275 225 7 4
PRAVASTATIN SODIUM 238 214 8 25
ALENDRONATE SODIUM 219 216 9 14
LOVASTATIN 153 145 10 11
GABAPENTIN 153 109 10 10
ZOLPIDEM TARTRATE 143 94 12 20
FLUTICASONE PROPIONATE 140 120 13 23
ATENOLOL 138 119 14 19
LOSARTAN POTASSIUM 129 116 15 12
ATORVASTATIN CALCIUM 120 114 16 15
METOPROLOL TARTRATE 114 99 17 13
CITALOPRAM HBR 104 89 18 21
HYDROCODONE-ACETAMINOPHEN 104 78 S3 18 7
FUROSEMIDE 101 82 20 8
RANITIDINE HCL 97 79 21 32
GLIPIZIDE ER 96 76 22 81
FLUOXETINE HCL 89 57 23 41
TRIAMTERENE-HCTZ 89 83 23 51
PROAIR HFA 87 70 25 38
OXYCODONE-ACETAMINOPHEN 83 66 S2 26 43
PANTOPRAZOLE SODIUM 79 78 27 33
PAROXETINE HCL 73 54 28 49
TRAMADOL HCL 72 67 29 26
WARFARIN SODIUM 72 64 29 17
DONEPEZIL HCL 70 70 31 29
METOPROLOL SUCCINATE 70 70 31 16
BACLOFEN 69 45 33 107
IBUPROFEN 67 54 34 60
CIPROFLOXACIN HCL 66 57 35 58
ALLOPURINOL 54 49 36 27
AMITRIPTYLINE HCL 54 19 R 36 66
GLIPIZIDE 53 44 38 36
OXYCODONE HCL 53 37 S2 38 37
GLYBURIDE 53 47 R 38 57
SERTRALINE HCL 51 41 41 22
OXYBUTYNIN CHLORIDE 51 40 41 97
TRIAMCINOLONE ACETONIDE 50 40 43 113
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.